| Date
| Event
| Class
| Action |
|
After spending $71 million on advertising for its pain-killer drug Celebrex in the first nine months of this year, Pfizer bows to pressure from regulators and agrees to pull Celebrex ads from TV, radio, newspapers and magazines, effective immediately. A clinical trial demonstrated that the painkil ... |
|
profile |
|
Pfizer shares plung after the company announces its arthritis drug Celebrex posed "increased cardiovascular risk" when used in high doses. Celebrex is a COX-2 inhibitor drug similar to Vioxx, which Merck withdrew from the market in September over similar health issues. |
|
profile |
|
Researchers at the University of Pennsylvania say the arthritis drug Celebrex does not carry the same heart attack risks as the drug Vioxx. Research showed that the chances of having a heart attack are nearly three times greater in Vioxx users than in Celebrex users, but other studies are still bein ... |
|
profile |
|